February 21, 2024
Mitsubishi Tanabe Pharma said on February 20 that it has filed for regulatory approval of an OD tablet version of its SGLT2/DPP-4 combination drug Canalia (teneligliptin + canagliflozin). Canalia is a fixed-dose combination of the SGLT2 inhibitor Canaglu (canagliflozin) and...read more